HMPL 004

Drug Profile

HMPL 004

Alternative Names: HMPL-004

Latest Information Update: 01 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; Nutrition Science Partners
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I Ulcerative colitis

Most Recent Events

  • 20 Mar 2018 Phase-I clinical trials in Crohn's disease (In volunteers) in Australia (PO)(NCT03597971)
  • 20 Mar 2018 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Australia (PO)(NCT03597971)
  • 02 Aug 2016 Hutchinson MediPharma announces intention to submit IND application to FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top